publication . Article . 2019

Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate

Chin, Ken Lee; Collier, Timothy; Pocock, Stuart; Pitt, Bertram; McMurray, John JV; van Veldhuisen, Dirk J; Swedberg, Karl; Vincent, John; Zannad, Faiez; Liew, Danny;
Open Access
  • Published: 01 Jan 2019 Journal: Clinical Research in Cardiology, volume 108, pages 806-814 (issn: 1861-0684, eissn: 1861-0692, Copyright policy)
  • Publisher: Springer Science and Business Media LLC
BACKGROUND: Increased resting heart rate is a risk factor for cardiovascular mortality and morbidity. Mineralocorticoid receptor antagonists (MRAs) have been shown to improve cardiac sympathetic nerve activity, reduce heart rate and attenuate left ventricular remodelling. Whether or not the beneficial effects of MRA are affected by heart rate in heart failure patients with reduced ejection fraction (HFREF) is unclear. METHODS: We undertook a secondary analysis of data from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure study to assess if clinical outcomes, as well as the efficacy of eplerenone, varied according to heart rate ...
free text keywords: Cardiology and Cardiovascular Medicine, General Medicine, ClinicalTrials, gov identifier: NCT00232180, Heart rate, Aldosterone antagonists, Aldosterone, Heart failure, REDUCED EJECTION FRACTION, MILD PATIENTS HOSPITALIZATION, ATRIAL-FIBRILLATION, COST-EFFECTIVENESS, RISK, SPIRONOLACTONE, ASSOCIATION, IVABRADINE, SURVIVAL
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue